BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose
Polymerase (PARP1) through the mechanism of synthetic lethality. Several PARP inhibitors …

Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for
homologous recombination (HR), a pathway essential for DNA double-strand break repair …

The aim of this article is to describe the current and potential clinical translation of
pharmacological inhibitors of poly (ADP-ribose) polymerase (PARP) for the therapy of …

Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular
processes, such as replication, recombination, chromatin remodeling, and DNA repair …

Homologous recombination (HR) repair deficiency impairs the proper maintenance of
genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors represent one of the successful
novel approaches to targeted cancer treatment. Indeed, the US Food and Drug …

Simple Summary Targeted therapy has revolutionised oncological treatments in cancer with
great efficacy and a more tolerable side effect profile as compared to standard …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Poly (ADP-ribose) Polymerase (PARP) has a well-established role in DNA repair processes,
and small molecule inhibitors of PARP have been developed as chemotherapy sensitisers …

Poly (ADP-ribose) polymerase inhibitors (PARPis) have recently been approved for the
treatment of ovarian and breast cancers with BRCA mutations, as well as for maintenance …